No Data
No Data
Apellis Pharmaceuticals Is Maintained at Outperform by Baird
Apellis Pharmaceuticals Analyst Ratings
UBS Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $45
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $30 to $55
Earnings Call: Apellis Pharmaceuticals Q3 2024 Results Show Promise
Express News | RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $24
No Data
No Data